Stocks finished broadly lower Thursday and Treasury bond yields fell to five-month lows as investors feared the the spread of new coronavirus infections could stall global growth.
Here are some of the top gainers Thursday:
1. Overstock.com | Increase 4.6%
Overstock.com (OSTK) - Get Overstock.com, Inc. Report climbed after Needham initiated coverage of the online retailer with a buy rating and $150 price target while adding the company to the firm's conviction list. Analyst Anna Andreeva said she viewed Overstock as "one of the most interesting ideas in e-commerce."
2. Virgin Galactic | Increase 17%
Shares of Virgin Galactic (SPCE) - Get Virgin Galactic Report jumped after Cowen analyst Oliver Chen more than doubled his price target for the aerospace company, founded and partly owned by entrepreneur Richard Branson, to $51 from $23. That target is the highest on Wall Street, according to Bloomberg.
3. Biogen | Increase 3.9%
Biogen (BIIB) - Get Biogen Inc. Report rose after the Food and Drug Administration approved changes to the product information for its Alzheimer's-disease treatment, Aduhelm. With the changes, the label says the drug has not been studied in treating later stages of the disease and should be given to patients with "mild cognitive impairment or mild dementia stage of disease."
4. Golden Nugget Online | Increase 10%
Golden Nugget Online Gaming (GNOG) - Get GOLDEN NUGGET ONLINE GAMING, INC. Report jumped after B. Riley analyst David Bain initiated coverage of the company with a buy rating and $27 price target. The company's internet gaming focus, experiential casino site differentiation and "strong" branding offer investors a "more predictable, stickier, and profitable avenue to play online gaming growth than online sports betting," Bain said, according to the Fly.
5. Aerpio Pharmaceuticals | Increase 63%
Aerpio Pharmaceuticals (ARPO) - Get Aerpio Pharmaceuticals, Inc. Report climbed after H.C. Wainwright analyst Robert Burns upgraded the company to buy from neutral with a $22 price target. He said the company's reverse merger with privately held Aadi Bioscience "appears transformative."
The deal should put the combined company on a "solid path towards becoming a self-sustaining, commercial-stage enterprise with a differentiated lead product having applicability across multiple specialty oncology indications," he said, according to the Fly.